Coronary heart disease
Conditions
Interventions
Personalized group:Platelet function test
Standard group:Standard treatment
Sponsors
The First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged >18 years old; 2. Coronary angiography confirmed that there was at least one coronary artery stenosis >70%; or the degree of stenosis of the left main artery stenosis >50%; 3. At least one clinical phenotype of coronary heart disease is present: stable angina or acute coronary syndrome; 4. There must be an objective examination of evidence of myocardial ischemia: positive plate test, FFR<0.80, OCT, or IVUS, which suggest that the plaque is not stable; 5. Drugs banned in the protocol can not be used throughout the study; 6. PCI has been given a dose of duplicated anti-platelet drugs (ASA 300mg + clopidogrel 300mg); 7. To be able to sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Combined with severe valvular heart disease; 2. Combined with severe congenital heart disease; 3. Combined hyperthyroidism, anemia and other high-powered heart disease; 4. With pulmonary heart disease; 5. With hypertrophic obstructive cardiomyopathy; 6. Severe hypotension (SBP 160 mmHg before PCI, and / or DBP> 100 mmHg); 8. Liver dysfunction (defined as ALT or total bilirubin is greater than the normal upper limit of 3 times); 9. Renal insufficiency (defined as serum creatinine greater than 1.5 times the normal upper limit); 10. High-risk bleeding patients, such as thrombocytopenia, blood diseases and other diseases; 11. active peptic ulcer and skin ulcers; 12. A patient who is allergic to clopidogrel, tegrellol, or aspirin; 13. Patients with a history of cardiogenic shock within two weeks; 14. pregnant and lactating women, during treatment can not be strict contraception of women of childbearing age; 15. In the past 3 months participated in other clinical researchers; 16. Persons who do not have legal or legal competence; 17. Any condition that the investigator considers unsuitable for participation in the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| all-cause mortality;cardiac death;Combined ischaemic and bleeding endpoint [net clinical benefit]; | — |
Secondary
| Measure | Time frame |
|---|---|
| Stent thrombosis;bleeding events according to BARC;Non - fatal stroke;Heart failure;Nonfatal myocardial infarction;Target vessel reconstruction;rehospitalized;Hospitalization cost; | — |
Countries
China
Contacts
Public ContactXiang XIE
First Affiliatted Hospital of Xinjiang Medical University
Outcome results
None listed